Share this page!

Marty Makary MD, MPH Profile picture
Twitter logo
May 29 • 3 tweets • 2 min read
Brilliant re-analysis of the data the CDC used justify school masking. This new elegant study, using a larger population & longer study period, found that school masking was NOT associated with pediatric case rates. @TracyBethHoeg @aChandra_TO 1/3 papers.ssrn.com/sol3/papers.cf…
This study demonstrates how the CDC was cherry-picking data to support their school mask dogma. The article states that CDC's MMWR journal rejected publishing this re-analysis. Most likely because it exposed the CDCs salami-slicing of data & use of science as political propaganda
This week, 12 large US school districts re-instated mandatory cloth masking for all children (regardless of immune status). They should consider this important study & the others showing the futility of school mask mandates summarized here by @ifihadastick relevantdata.substack.com

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Marty Makary MD, MPH

Marty Makary MD, MPH Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @MartyMakary

Marty Makary MD, MPH Profile picture
Mar 29
Is this following the science?? FDA will authorize 4th doses this week by bypassing the typical voting process of their external experts. FDA will then convene them after the authoriz to "discuss". It's like a judge issuing a verdict and then having lawyers make their arguments.
There is zero clinical data that a 4th dose reduces hospitalization risk. There isn't even any evidence that a 3rd dose reduces hospitalization risk in young people.
The editor of the New Engl Journal, who sits on VRBPAC, has said he "hadn't yet seen enough data on fourth doses to make a determination about whether they are needed for anyone beyond those who are already recommended to get them -- adults who are severely immune deficient"
Read 5 tweets
Marty Makary MD, MPH Profile picture
Feb 23
After a year of urging the CDC to increase the interval btw the first 2 mRNA doses (to lower complications & increase durability), the CDC finally did it--changed their rec, acknowledging the longer spacing "may reduce the risk for severe side effects" 1/4 thehill.com/homenews/admin…
Ever wonder why a quarter of America was knocked down/in bed for a day after their 2nd dose? The interval was too short.

As several of us argued from the start, no vaccine has multiple doses given that close together. But the FDA and CDC were too rigid to listen.

2/4
How many people were hurt by the CDC's stubbornness?

The original 3/4 week interval between doses was chosen (with good intentions) to get the trial done quickly, but by mid-spring 2021, ample data emerged favoring a longer interval: medpagetoday.com/opinion/marty-…

3/4
Read 4 tweets
Marty Makary MD, MPH Profile picture
Nov 28, 2021
With Omicron, therapeutics are once again missing from the Covid conversation. Molnupiravir & Paxlovid both block virus replication and thus work across variant strains. Fluvoxamine acts on a common inflammatory pathways so would logically work with omicron infections as well.
I'm constantly amazed at how little awareness and coverage there has been on fluvoxamine, which is available now. It's not a medication with mixed results/controversy. A 2nd RCT reported a 91% reduction in Covid deaths. It can also be used in combination with new antivirals.
There has been such an intense focus on vaccines that therapeutics have been understated and often overlooked. Even some physicians are unaware of the fluvoxamine studies (maybe because Drs. Fauci and Walensky have not talked about them). Vaccines save lives but so do medications
Read 4 tweets
Marty Makary MD, MPH Profile picture
Nov 9, 2021
Based on the data: We should not be giving healthy kids a 2nd vax dose at a 3wk interval, esp boys where 1/7K get myocarditis and 1/136 of them died, i.e. from the vax itself(NEJM study). Vax deaths could approximate Covid deaths in boys 5-11 w/no comorbid wsj.com/articles/shoul…
CDC: 94 Covid deaths/2yrs (incl when Tx was crude & Covid rates higher) out of 28M kids5-11. Nearly all likely had a comorb (extrap from our prior study, adolesc hosp study/known under-coding of obesity, word on the ground). CDC still won't tell us # child deaths in healthy kids.
Based on the data of kids w/ NO comorbid, an estimated 0-10 kids 5-11 have ever died of Covid

VS.

Approx 15 would die from the vax 2nd dose (extrap from adolescents). The case to vax kids w/a comorbid is strong. The case for a 2nd vax dose in healthy kids is far from compelling
Read 5 tweets
Marty Makary MD, MPH Profile picture
Oct 18, 2021
With every new Covid death I hear about, including the great Colin Powell, I'm increasingly frustrated by the fact that Molnupiravir is not offered under compassionate use. The drug cut Covid deaths to zero in the phase 3 trial of high-risk patients. wsj.com/articles/fda-c…
The clinical benefit to high-risk patients was so dramatic, that they had to stop the study early.
Many other therapeutics that are safe are being overlooked. Steroid nebulizer, hypertonic saline nasal spray, and Fluoxamine all have placebo-controlled trial data that shows a significant clinical benefit: covid19treatmentguidelines.nih.gov/therapies/immu…
Read 5 tweets
Marty Makary MD, MPH Profile picture
Oct 8, 2021
MP is a powerful Covid drug and should be offered to dying patients right now on a COMPASSIONATE USE BASIS just as monoclonal antibodies & convalescent plasma were given on a compassion use basis before their EUAs were issued, as I explain in today's @WSJ wsj.com/articles/fda-c…
In terms of survival benefit, Molnupiravir blows Regeneron's therapy out of the water. In fact, no one who got Molnupiravir died and the treatment effect was so profound that they had to stop the trial early. Now let's cut the red tape and save lives.
To get an FDA expanded access protocol (EAP) approved, Merck has to agree to it (they haven't indicated they will), doctors have to set up a protocol (a lot of red tape) &the FDA has to approve (they're being passive despite authoring the regulatory hurdles for compassionate use)
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(